MEDIPOST Registers European Patent for the Mesenchymal Stem Cell Culture Method2019/07/24STEM CELL THERAPEUTIC
MEDIPOST Registers the Canadian Patent for a Mesenchymal Stem Cell Culture Method2019/06/26STEM CELL THERAPEUTIC
MEDIPOST’s Injectable Cell Therapeutic for Knee Osteoarthritis Receives Phase 1 Clinical Trial Approval2019/05/31STEM CELL THERAPEUTIC
MEDIPOST, announces a domestic and international clinical experience at the ISCT annual meeting2019/05/30STEM CELL THERAPEUTIC
Results from the US Clinical Trial of PNEUMOSTEM for Treating Lung Disease is Published in International Journal2019/05/13STEM CELL THERAPEUTIC
MEDIPOST Clears Product Approval Renewal of CARTISTEM by the Ministry of Food and Drug Safety(MFDS)2019/03/26STEM CELL THERAPEUTIC
MEDIPOST, acquires a Japanese patent for the mesenchymal stem cell culture method2019/01/30STEM CELL THERAPEUTIC
MEDIPOST, ends phase I and II clinical trials with PNEUMOSTEM, the effective treatment of BPD for preterm infants2019/01/08STEM CELL THERAPEUTIC
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®2023/12/27
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billion, to be Used for Global Market Expansion Including the U.S.2023/10/04
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal2023/05/02
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan2023/01/16
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01